Cutaneous reactions caused by nitrofurazone
| Autor: | Goknur Ozaydin-Yavuz, Ayse Serap Karadag, Ibrahim Halil Yavuz, Mehmet Ali Bilgili, Serap Gunes Bilgili |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2019 |
| Předmět: |
Drug
lcsh:Internal medicine medicine.medical_specialty media_common.quotation_subject Erythroderma Topical Product Dermatology Atopy 030207 dermatology & venereal diseases 03 medical and health sciences 0302 clinical medicine lcsh:Dermatology medicine Immunology and Allergy lcsh:RC31-1245 Allergic contact dermatitis Sensitization media_common Nitrofurazone Original Paper business.industry nitrofurazone lcsh:RL1-803 medicine.disease Hypersensitivity reaction medicine.anatomical_structure business allergic contact dermatitis |
| Zdroj: | Advances in Dermatology and Allergology/Postȩpy Dermatologii i Alergologii Advances in Dermatology and Allergology, Vol 36, Iss 4, Pp 398-402 (2019) |
| ISSN: | 2299-0046 1642-395X |
| Popis: | Introduction Allergic contact dermatitis (ACD) is a form of dermatitis due to type 4 hypersensitivity reaction that occurs when the skin comes into contacts with the topical product. Topical nitrofurazone is a widely used antimicrobial drug in our country which is well known to cause ACD. Aim In this study, ACD cases with different clinical features attributed to the use of nitrofurazone were evaluated. Material and methods Patients hospitalized in our clinic between 2013 and 2017 with ACD diagnosis due to nitrofurazone were evaluated. The patient age, gender, atopy histories, clinical features, dissemination of the lesions, treatment given were reviewed. Results In a 5-year period, 58 cases were identified and their data were analysed. Twelve patients were female (21%), 46 patients were male (79%). Clinical presentations were dyshidrosiform (45%), excoriated papules and plaques (33%), combined (21%), and erythroderma in one patient. The dissemination was generalized in 34 patients, localized in 14 patients, and local spread in 10 patients. The mean hospitalization time was 7 ±3 days, and ranged from 3 to 18 days. Conclusions There may be widespread and severe ACD due to the use of nitrofurazone. Topical nitrofurazone should not be applied on damaged skin as sensitization may develop. Patients and physicians should be aware of the ACD risk associated with topical nitrofurazone, which is also commonly used as self-medication, physicians should take a detailed history of the drug use and products containing nitrofurazone should not be used in conditions where skin integrity is not intact, whenever possible. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|